Session Title: Free Paper Session 22: AMD V
Session Date/Time: Sunday 10/09/2017 | 08:00-09:30
Paper Time: 09:06
Venue: Room 115
First Author: : C.Iovino ITALY
Co Author(s): : G. Caminiti R. Serra E. Peiretti
The aim of the study is to report long-term results of a consecutive series of naïve patients with neovascular age-related macular degeneration (AMD) treated with intravitreal ranibizumab and followed using a new strategy, called “wait and extend”.
102 eyes of 102 patients under anti-VEGF intravitreal injection (IVT) were monitored on the basis of multimodal imaging including fluorescein angiography, indocyanine green angiography, optical coherence tomography up to 6 years. The treatment strategy consisted of a first IVT and if there was no sign of activity the follow-up checks period was extended up to a maximum of 90 days. Best corrected visual acuity was evaluated baseline and at each follow up visit
102 eyes were treated and followed for a maximum of 6 years. The mean (± SD) change from baseline in visual acuity was +5.6 (±16.1) ETDRS letters (p < 0.05) at 1 year of follow-up, +5.3 (±20.4) ETDRS letters (p < 0.05) at 2 years, and +3.7 (±19.2) ETDRS letters (p = NS) at 3 years of follow-up; visual acuity finally returned to a value of -0.7 (±15.5) ETDRS letters at 6 years of follow-up. The average number of injections (±SD) was 3.1 (±1.1) in the first year, 1.2 (±1.1) in the second, 1.7 (±1.5) in the third, 1.7 (±1.2) in the fourth, 1.5 (±1.5) and 1.2 (±1.1) in the fifth and sixth respectively.
The wait and extend regimen allowed a good vision stabilization in wet AMD patients with a reduced burden of injections